Translation
en
Default locale
en
Fallback locale
Messages
Defined 62
These messages are correctly translated into the given locale.
| Locale | Domain | Times used | Message ID | Message Preview |
|---|---|---|---|---|
| en | messages | 1 | drug.shortage.report | Drug Shortage Report for |
| en | messages | 1 | home | Home |
| en | messages | 1 | search | Search |
| en | messages | 1 | reports | Reports |
| en | messages | 1 | products | Products |
| en | messages | 1 | rws.search | Summary Report |
| en | messages | 1 | tier3.shortages | Tier 3 Drug Shortages |
| en | messages | 1 | blog | About & Resources |
| en | messages | 1 | contact | Contact |
| en | messages | 1 | submit.report | Submit Report |
| en | messages | 1 | shortage.report | Shortage report |
| en | messages | 1 | discontinuance.report | Discontinuation report |
| en | messages | 1 | profile | Profile |
| en | messages | 1 | version.number | Version Number |
| en | messages | 1 | last.updated | Date Updated |
| en | messages | 1 | language | Language |
| en | messages | 11 | restore | Restore |
| en | messages | 6 | en | English |
| en | messages | 11 | compare | Compare |
| en | messages | 5 | fr | French |
| en | messages | 1 | skip.links | Skip links |
| en | messages | 1 | skip.to.main.content | Skip to main content |
| en | messages | 1 | login | Log in |
| en | messages | 1 | create.account | Create Account |
| en | messages | 1 | main.navigation | Main navigation |
| en | messages | 7 | click.for | Click for |
| en | messages | 1 | last.updated.on | Last updated on |
| en | messages | 1 | history | History |
| en | messages | 1 | report.id | Report ID |
| en | messages | 1 | din | Drug Identification Number |
| en | messages | 1 | brand.name | Brand name |
| en | messages | 1 | common.name | Common or Proper name |
| en | messages | 1 | company | Company Name |
| en | messages | 1 | market_status | Market Status |
| en | messages | 1 | en_ingredients | Active Ingredient(s) |
| en | messages | 1 | drug_strength | Strength(s) |
| en | messages | 1 | drug_dosage_form | Dosage form(s) |
| en | messages | 1 | drug_route | Route of administration |
| en | messages | 1 | drug_package_gtin | Packaging size |
| en | messages | 1 | atc_number | ATC code |
| en | messages | 1 | atc_description | ATC description |
| en | messages | 1 | shortage_reason | Reason for shortage |
| en | messages | 1 | anticipated_start_date | Anticipated start date |
| en | messages | 1 | actual_start_date | Actual start date |
| en | messages | 1 | estimated_end_date | Estimated end date |
| en | messages | 1 | actual_end_date | Actual end date |
| en | messages | 1 | shortage_status | Shortage status |
| en | messages | 1 | active_confirmed | Actual shortage |
| en | messages | 1 | updated.date | Updated date |
| en | messages | 1 | en_comments | Company comments |
| en | messages | 1 | hc_en_comments | Health Canada comments |
| en | messages | 1 | tier3.status | Tier 3 Status |
| en | messages | 1 | contact.address | Contact Address |
| en | messages | 1 | company_contact_info | Company contact information |
| en | messages | 1 | version.history | Version History |
| en | messages | 1 | version.history.description | Click on "Compare" below to view the full report history and compare to other versions. |
| en | messages | 1 | sort.by | Sort by |
| en | messages | 2 | asc | ascending order |
| en | messages | 1 | click.sort.by | Click to sort by |
| en | messages | 1 | current.page | Current page |
| en | messages | 1 | of.total.pages | of total pages |
| en | messages | 1 | pagination.format | Showing %d to %d of %d |
Fallback 0
These messages are not available for the given locale but Symfony found them in the fallback locale catalog.
No fallback translation messages were used.
Missing 16
These messages are not available for the given locale and cannot be found in the fallback locales. Add them to the translation catalogue to avoid Symfony outputting untranslated contents.
| Locale | Domain | Times used | Message ID | Message Preview |
|---|---|---|---|---|
| en | messages | 1 | 241524 | 241524 |
| en | messages | 1 | 02248077 | 02248077 |
| en | messages | 1 | PEGASYS | PEGASYS |
| en | messages | 1 | peginterferon alfa-2A injection | peginterferon alfa-2A injection |
| en | messages | 1 | PHARMAAND GMBH | PHARMAAND GMBH |
| en | messages | 1 | MARKETED | MARKETED |
| en | messages | 1 | PEGINTERFERON ALFA-2A | PEGINTERFERON ALFA-2A |
| en | messages | 1 | 180MCG | 180MCG |
| en | messages | 1 | SOLUTION | SOLUTION |
| en | messages | 1 | SUBCUTANEOUS SUBCUTANEOUS | SUBCUTANEOUS SUBCUTANEOUS |
| en | messages | 1 | pre-filled syringes 180 mcg/0.5 mL | pre-filled syringes 180 mcg/0.5 mL |
| en | messages | 1 | L03AB | L03AB |
| en | messages | 1 | IMMUNOSTIMULANTS | IMMUNOSTIMULANTS |
| en | messages | 1 | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| en | messages | 1 | The sole manufacturer of Pegasys® API, Roche Diagnostics GmbH produced a final batch of peginterferon alfa-2a in 2017. Establishment of new API manufacturer for peginterferon alfa-2a, Loba biotech GmbH, Fischamend, Austria (affiliate of pharmaand GmbH) remains in progress. Before Roche Diagnotics GmbH permanently decommissioned the API production line, they produced a final batch in 2017 which was estimated to cover global demand for approximately 10 years. Pegasys® product demand has increased significantly due to recent changes in the market. As a result, the final product batch produced by Roche will not last for the intended period of approximately 10 years, and pharmaand GmbH (pharma&) has looked to expedite the manufacturing plan. pharma& committed to investing in the ongoing development and future certification of our bio-manufacturing capabilities at our wholly-owned manufacturing plant in Austria, Loba biotech GmbH.This is a significant investment and was required to transfer the active pharmaceutical ingredient (API) in Pegasys® to our new facility, which is a complex biologic treatment to manufacture, requiring 18 purification stages to ensure the highest quality and safety for the patient. | The sole manufacturer of Pegasys® API, Roche Diagnostics GmbH produced a final batch of peginterferon alfa-2a in 2017. Establishment of new API manufacturer for peginterferon alfa-2a, Loba biotech GmbH, Fischamend, Austria (affiliate of pharmaand GmbH) remains in progress. Before Roche Diagnotics GmbH permanently decommissioned the API production line, they produced a final batch in 2017 which was estimated to cover global demand for approximately 10 years. Pegasys® product demand has increased significantly due to recent changes in the market. As a result, the final product batch produced by Roche will not last for the intended period of approximately 10 years, and pharmaand GmbH (pharma&) has looked to expedite the manufacturing plan. pharma& committed to investing in the ongoing development and future certification of our bio-manufacturing capabilities at our wholly-owned manufacturing plant in Austria, Loba biotech GmbH.This is a significant investment and was required to transfer the active pharmaceutical ingredient (API) in Pegasys® to our new facility, which is a complex biologic treatment to manufacture, requiring 18 purification stages to ensure the highest quality and safety for the patient. |
| en | messages | 1 | Yes | Yes |